Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients

Journal of Diabetes and its Complications

Volumn 29, Issue 3, 2015, Pages 413-421

  Yabe, Daisuke ^a,b   Kuroe, Akira ^a,g   Watanabe, Koin ^a   Iwasaki, Masahiro ^a,b   Hamasaki, Akihiro ^c,h   Hamamoto, Yoshiyuki ^c,h   Harada, Norio ^c   Yamane, Shunsuke ^c   Lee, Soushou ^d   Murotani, Kenta ^e   Deacon, Carolyn F ^f   Holst, Jens J ^f   Hirano, Tsutomu ^d   Inagaki, Nobuya ^c   Kurose, Takeshi ^a   Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGOYA UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g Hikone Municipal Hospital   (Japan)

^h Kitano Hospital   (Japan)

Author keywords

GIP; GLP 1; Glucagon; Hyperglycemia; Insulin

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; DISEASE DURATION; FEMALE; GLUCAGON RELEASE; GLUCOSE TOLERANCE; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRIENT UPTAKE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION; AGED; CLINICAL TRIAL; EATING; FOOD; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; SECRETION (PROCESS); TIME FACTOR; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; EATING; FEMALE; FOOD; GLUCAGON; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TIME FACTORS; YOUNG ADULT;

EID: 84925346691     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.12.010     Document Type: Article

References (52)

1. B. Ahren Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: Outcome of a 12-year prospective study in postmenopausal Caucasian women Diabetes 58 2009 726 731
2. B. Ahren, and H. Larsson Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations Diabetologia 44 2001 1998 2003
3. W. Alsalim, B. Omar, and G. Pacini Incretin and islet hormone responses to meals of increasing size in healthy subjects The Journal of Clinical Endocrinology and Metabolism 2014 10.1210/jc.2014-2865 (Epub ahead of print)
4. B.A. Aulinger, A. Bedorf, and G. Kutscherauer Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade Diabetes 63 2014 1079 1092
5. J.I. Bagger, F.K. Knop, and A. Lund Impaired regulation of the incretin effect in patients with type 2 diabetes The Journal of Clinical Endocrinology and Metabolism 96 2011 737 745
6. M.J. Bak, N.W. Albrechtsen, and J. Pedersen Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans European Journal of Endocrinology 170 2014 529 538
7. M.J. Bak, N.J. Wewer Albrechtsen, and J. Pedersen Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-1 measurements in clinical studies Diabetes, Obesity & Metabolism 16 2014 1155 1164
8. S. Calanna, M. Christensen, and J.J. Holst Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: Systematic review and meta-analyses of clinical studies Diabetologia 56 2013 965 972
9. S. Calanna, M. Christensen, and J.J. Holst Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: Systematic review and meta-analysis of clinical studies Diabetes Care 36 2013 3346 3352
10. M. Christensen, S. Calanna, and A.H. Sparre-Ulrich Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes Diabetes 64 2014 72 78
11. M. Christensen, L. Vedtofte, and J.J. Holst Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans Diabetes 60 2011 3103 3109
12. M.J. Davies, G. Rayman, and A. Grenfell Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance Diabetic Medicine 11 1994 432 436
13. C.F. Deacon, and J.J. Holst Immunoassays for the incretin hormones GIP and GLP-1 Best Practice & Research. Clinical Endocrinology & Metabolism 23 2009 425 432
14. D.J. Drucker Incretin action in the pancreas: Potential promise, possible perils, and pathological pitfalls Diabetes 62 2013 3316 3323
15. M. Fukushima, H. Suzuki, and Y. Seino Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes Diabetes Research and Clinical Practice 66S 2004 S37 S44
16. S.M. Haffner, H. Miettinen, and S.P. Gaskill Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance Diabetologia 39 1996 1201 1207
17. P.V. Hojberg, T. Vilsboll, and R. Rabol Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes Diabetologia 52 2009 199 207
18. J.J. Holst The physiology of glucagon-like peptide 1 Physiological Reviews 87 2007 1409 1439
19. M. Iwata, S. Maeda, and Y. Kamura Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals Diabetes Care 35 2012 1763 1770
20. K. Kawai, Y. Murayama, and Y. Okuda Postprandial glucose, insulin and glucagon responses to meals with different nutrient compositions in non-insulin-dependent diabetes mellitus Endocrinologia Japonica 34 1987 745 753
21. D. Kawamori, H.J. Welters, and R.N. Kulkarni Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction Advances in Experimental Medicine and Biology 654 2010 421 445
22. F.K. Knop, T. Vilsboll, and P.V. Hojberg Reduced incretin effect in type 2 diabetes: Cause or consequence of the diabetic state? Diabetes 56 2007 1951 1959
23. H. Kurahachi, Y. Seino, and M. Ikeda Insuppressibility of plasma glucagon by orally or intravenously administered glucose in diabetes mellitus Endocrinologia Japonica 24 1977 413 419
24. A. Mari, A. Tura, and G. Pacini Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes Diabetic Medicine 25 2008 671 677
25. L. Marroqui, P. Alonso-Magdalena, and B. Merino Nutrient regulation of glucagon secretion: Involvement in metabolism and diabetes Nutrition Research Reviews 2014 1 15
26. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
27. N. Mentis, I. Vardarli, and L.D. Kothe GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes Diabetes 60 2011 1270 1276
28. J.B. Moller, M. Pedersen, and H. Tanaka Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians Diabetes Care 37 2014 796 804
29. M.A. Nauck, E. Homberger, and E.G. Siegel Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses The Journal of Clinical Endocrinology and Metabolism 63 1986 492 498
30. M.A. Nauck, I. Vardarli, and C.F. Deacon Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia 54 2010 10 18
31. T. Nishino, T. Kodaira, and S. Shin Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment Clinical Chemistry 27 1981 1690 1697
32. U.E. Ntuk, J.M. Gill, and D.F. Mackay Ethnic-specific obesity cutoffs for diabetes risk: Cross-sectional study of 490,288 UK Biobank participants Diabetes Care 37 2014 2500 2507
33. T.J. Oh, M.Y. Kim, and J.Y. Shin The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes Clinical Endocrinology 80 2014 221 227
34. M. Prentki, F.M. Matschinsky, and S.R. Madiraju Metabolic signaling in fuel-induced insulin secretion Cell Metabolism 18 2013 162 185
35. L.J. Raffel, D.C. Robbins, and J.M. Norris The GENNID Study. A resource for mapping the genes that cause NIDDM Diabetes Care 19 1996 864 872
36. G.M. Reaven, Y.D. Chen, and A. Golay Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus The Journal of Clinical Endocrinology and Metabolism 64 1987 106 110
37. J.M. Rijkelijkhuizen, K. McQuarrie, and C.J. Girman Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses Metabolism 59 2010 502 511
38. Y. Seino, Y. Goto, and H. Kurahachi Alteration of plasma glucagon response to arginine after treatment in patients with diabetes mellitus, cushing's syndrome and hypothyroidism Hormone and Metabolic Research 9 1977 28 32
39. Y. Seino, M. Ikeda, and H. Kurahachi Failre of suppress plasma glucagon concentrations by orally administered glucose in diabetic patients after treatment Diabetes 27 1978 1145 1150
40. Y. Seino, K. Nanjo, and N. Tajima Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus Journal of Diabetes Investigation 1 2010 212 228
41. Y. Seino, and D. Yabe GIP and GLP-1: Incretin actions beyond pancreas Journal of Diabetes Investigation 4 2013 108 130
42. S. Seino, T. Shibasaki, and K. Minami Dynamics of insulin secretion and the clinical implications for obesity and diabetes Journal of Clinical Investigation 121 2011 2118 2125
43. P. Shah, A. Vella, and A. Basu Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus The Journal of Clinical Endocrinology and Metabolism 85 2000 4053 4059
44. T. Taminato, Y. Seino, and Y. Goto Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat Diabetes 26 1977 480 484
45. R.H. Unger The Banting Memorial Lecture 1975. Diabetes and the alpha cell Diabetes 25 1976 136 151
46. R.H. Unger, and A.D. Cherrington Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover Journal of Clinical Investigation 122 2012 4 12
47. T. Vilsboll, T. Krarup, and S. Madsbad Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients Diabetologia 45 2002 1111 1119
48. C. Weyer, C. Bogardus, and D.M. Mott The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus Journal of Clinical Investigation 104 1999 787 794
49. D. Yabe, A. Kuroe, and S. Lee Little enhancement of meal-induced GLP-1 secretion in Japanese: Comparison of type 2 diabetes and healthy controls Journal of Diabetes Investigation 1 2010 56 59
50. D. Yabe, and Y. Seino Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes Expert Review of Endocrinology and Metabolism 9 2014 659 670
51. D. Yabe, K. Watanabe, and K. Sugawara Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes Journal of Diabetes Investigation 3 2012 70 79
52. Y. Yamada, K. Fukuda, and S. Fujimoto SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes Diabetes Research and Clinical Practice 74 2006 222 226